S. enterica isolates from pigs and broilers was demonstrated. Only the plasmid from the human E. coli isolate differed in RFLP fingerprint pattern from the other bla CTX-M-2 -carrying plasmids. Southern blot hybridization with a bla CTX-M-2 probe revealed a .10 kb EcoRI fragment in the plasmids from the porcine and broiler E. coli isolates and from the Salmonella Virchow CODA-1 isolate. Two EcoRI fragments of 6 and 10 kb were found in the plasmid from the human E. coli isolate and in the plasmid from the Salmonella Virchow 142-1 isolate. 2 For the bla CTX-M-15 -carrying plasmids, results of RFLP analysis were identical except for the plasmid from the human E. coli strain. For the animal strains, Southern blot hybridization with a bla CTX-M-15 probe revealed two EcoRI fragments of 6.5 and 7 kb and one 5 kb PstI fragment. The plasmid from the human E. coli strain showed 5 and .10 kb EcoRI fragments and a 5.5 kb PstI fragment. The Southern blot results suggest the existence of two copies of the tested ESBLs on their $150 kb plasmids.
The differences seen in the RFLP analyses for the bla CTX-M-2 -and bla CTX-M-15 -carrying plasmids may possibly reflect the rapid evolution of these plasmids as they were exposed to different environmental stresses. The human, porcine and poultry environments may be experienced by bacteria in different ways.
In summary, ESBL resistance plasmids appear to move readily between different microorganisms and different ecosystems. TEM-52-carrying cephalosporin-resistant organisms may have been transmitted from food animals to humans, or vice versa. 3 For the CTX-M-2-or CTX-M-15-carrying cephalosporinresistant organisms, exchange between food animals and humans, however, remains unclear, mainly due to the unknown plasticity and evolutionary speed of the plasmids carrying them. Sir, Bartonella species are Gram-negative bacilli that belong to the alpha 2 subgroup of Proteobacteria. Due to the fastidious nature of these bacteria and the limited number of available isolates worldwide, there are few data on in vitro susceptibility to antibiotics. There are anecdotal reports of the use of fluoroquinolones in the treatment of infections due to Bartonella henselae or Bartonella quintana.
1 However, failures or relapses have been observed with these compounds suggesting that antibiotic resistance may develop during treatment.
1,2 Thus, deciphering the molecular mechanism of resistance for these bacteria remains important since in vivo data do not correlate well with in vitro findings. Bacterial resistance to fluoroquinolones can essentially develop through two main mechanisms, namely a decrease in the intra-bacterial concentration of the drug, or alterations in the drug's target enzymes. 3 Target site alteration results from mutations in the chromosomal genes encoding the quinolone resistance-determining region (QRDR) of DNA gyrase and topoisomerase IV. 3 We have recently reported that fluoroquinolone-resistant mutants can be easily obtained in vitro for Bartonella bacilliformis suggesting that these antibiotics should not be used to treat infectious due to this bacterium, i.e. Carrion's disease. 4 Moreover, we have demonstrated that an intrinsic mutation in the QRDR region of DNA gyrase confers heterogeneity of susceptibility to fluoroquinolones and a low level of resistance for all Bartonella species. 5 The aim of the present study was to expand our knowledge on fluoroquinolone resistance for the two main Bartonella species encountered in humans, i.e. B. henselae, the agent of cat scratch disease (CSD), and B. quintana, the agent of trench fever. 1 B. quintana strain Oklahoma and B. henselae strain Houston-1 were used in this study and were cultivated on Columbia 5% sheep blood agar plates (bioMérieux, Marcy l'É toile, France) at 378C for 6 days in a 5% CO 2 atmosphere. Selection of antibiotic-resistant mutants was performed by serial passages of the bacteria on a blood agar plate containing an antibiotic disc of ciprofloxacin (5 mg) (Mast Diagnostics, Amiens, France) as previously described. 4 MICs were recorded at each passage using Etest strips (AB BIODISK, Solna, Sweden). DNA was extracted, from the susceptible strains and from the antibiotic-resistant mutants, using a QIAamp tissue kit (QIAGEN, Hilden, Germany), and screened by PCR amplification and DNA sequencing using specific oligonucleotide primers targeting a portion of the Bartonella gyrA, gyrB, parC and parE genes ( Table 1) . These primers were designed in order to include the areas that concern the most common quinolone resistance mutations in the gyrA, gyrB, parC and parE genes (based on Escherichia coli) and according to the available complete genome sequence of other Bartonella species including B. henselae, B. quintana and B. bacilliformis (http://www.genome. jp/kegg/). The obtained nucleotide sequences of candidate genes were compared using the CLUSTALW program (http://www.ebi. ac.uk/clustalw/) to look at possible mutations known to be associated with antibiotic resistance. Nucleotide sequences were translated into protein sequences using the DNA to protein translation program (http://bio.lundberg.gu.se/edu/translat.html). The known original protein sequences of E. coli (K-12 MG1655), encoded by gyrA, gyrB, parC and parE genes, were retrieved from the KEGG web site (www.genome.jp) and used for alignments.
The ciprofloxacin-resistant strain of B. henselae was obtained in vitro after only four passages and for B. quintana after five passages (MICs for both strains increased from 0.38 to .32 mg/L). When compared with the susceptible strains, the ciprofloxacin-resistant B. quintana and B. henselae harboured a C-549!T transition (E. coli numbering) of the gyrA gene, encoding predicted amino acid change Asp-87!Asn in the gyrase A protein. No mutations were found in the gyrB, parC and parE genes.
In the present study, we describe the molecular characterization of in vitro resistance to ciprofloxacin of B. henselae and B. quintana strains. Mutations at codons Ser-83 and Asp-87 of gyrA appear most frequently and result in high levels of quinolone resistance. 5 Bartonella spp. present a natural Ser-83!Ala mutation (E. coli numbering) in the QRDR region of the DNA gyrase that results in heterogeneity of susceptibility to fluoroquinolones. 5 A Asp-87!Asn (E. coli numbering) mutation in the QRDR region of DNA gyrase, conferring high-level fluoroquinolone resistance, had already been identified in a ciprofloxacinresistant B. bacilliformis mutant obtained in vitro. 4, 6 Mutation Ser-83!Ala decreases the susceptibility to fluoroquinolones, whereas the double mutation Ser-83!Ala and Asp-87!Gly results in a high level of resistance to all quinolone compounds. 3 In conclusion, we demonstrated that both B. henselae and B. quintana can easily become resistant to fluoroquinolones in vitro. As a result, we do not recommend fluoroquinolones for the treatment of any bartonelloses, especially chronic manifestations.
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